Featured Editorial

1. Money In The Bank: Why 2025's Setbacks Were The Foundation RNA Needed 1/5/2026

   I saw 2025 as a year that was foundational for our efforts to learn more about the biology and function of our products. However, there were two developments in particular that, to me, encapsulated the trials, tribulations, and ultimately the success of an industry that is doing its damnedest to answer one of the biggest questions facing us: “Why RNA?”  

2. In Vivo LNP-Engineered Cytokine-Armored CAR Cells For Solid Tumors 12/23/2025

   By injecting lipid-based nanoparticles encapsulating mRNA and encoding the CAR directly into the bloodstream, developers can effectively reprogram the patient's own immune cells in situ.

3. Biology, Specificity, and the Rules of RNA Business Strategy In 2026 12/22/2025

   Here, in part 3 of this outlook series, we continue our forward-looking conversation with Signify Bio CBO, Renee Williams, who shares why she hopes 2026 is the year we “focus in” on three important factors — namely our biology, our platforms, and our IP — and what this looks like/means strategically.  

4. Powering Cell Therapies With RNA: A New Code For Engineered Immunity 12/19/2025

   RNA is redefining cell therapy engineering—enabling transient, programmable control of immune and stem cells while simplifying manufacturing, improving safety, and accelerating scalable, virus-free workflows.

5. Beyond The Hype: How 2025's Successes & Realities Will Shape mRNA In 2026 12/16/2025

   Here, in part two of this multi-part series, we hear from Melissa Bonner, CSO of nChroma Bio and Andy Geall, CDO of Replicate Biosciences, who call attention to several developments of the past year they’ve been watching and how they see these developments informing our conversations about and work with mRNA in 2026 and beyond. 

6. What 2025 FDA Warning Letters Tell Us About GMP Compliance 12/15/2025

   This analysis identifies key compliance trends and regional disparities by examining the 2025 U.S. FDA warning letters issued to drug product manufacturers posted between Jan. 1 and Dec. 9, 2025.

7. Why RNA Tech Transfer Is So Hard — And How the Field Can Fix It 12/11/2025

   A closer look at why RNA tech transfer remains one of the field’s toughest bottlenecks — and the practical steps developers and CDMOs can take to finally streamline the path to GMP.

8. Making Personalized Cancer Vaccines Reality: The Manufacturing Challenge Ahead 12/5/2025

   Personalized cancer vaccines are becoming feasible, but scaling fast, affordable, data-driven manufacturing is the central challenge to bringing these individualized therapies to more patients.

9. Strained Manufacturing, Complexity Stymie In Vivo Progress 12/4/2025

    Explicitly mapping delivery challenges to the associated GMP process steps converts biological risk into operational risk.

10. To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem 12/4/2025

    The choice of delivery dictates the complexity of manufacturing, which in turn determines the eventual cost and accessibility of the therapy.